Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTXZ), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT) is a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a strong focus on metastatic breast cancer. The news flow around BriaCell centers on its clinical trial progress, scientific presentations, collaborations, and capital markets activity, all of which are relevant for investors and healthcare professionals tracking the company’s development.
Recent news releases highlight pivotal Phase 3 trial updates for Bria-IMT in advanced metastatic breast cancer, including enrollment milestones and plans for interim analyses of overall survival. BriaCell frequently reports on Phase 2 and Phase 3 clinical data, such as survival outcomes, progression-free survival signals, and biomarker findings presented at major oncology conferences like the San Antonio Breast Cancer Symposium (SABCS).
Another key news theme is BriaCell’s work on its Bria-OTS and Bria-OTS+ platforms. Company announcements have described clinical observations from the Bria-OTS Phase 1/2a metastatic breast cancer study, including sustained complete resolution of a lung metastasis in a treated patient, as well as preclinical data showing robust immune activation and anti-cancer activity for Bria-OTS+ candidates Bria-BRES+ and Bria-PROS+.
News items also cover strategic collaborations and subsidiary activities, such as the AI-driven discovery partnership between BriaPro Therapeutics Corp., BriaCell’s wholly owned subsidiary, and Receptor.AI to design isoform-selective kinase inhibitors. In addition, BriaCell issues updates on SEC registration statements and warrant offerings, which are important for understanding its capital structure and financing plans.
Visitors to this news page can review company-issued press releases that document BriaCell’s clinical milestones, scientific recognition in publications such as Nature Medicine, and ongoing efforts to develop immunotherapies for patients with limited treatment options.
BriaCell Therapeutics (NASDAQ: BCTX) reported sustained complete resolution of lung metastasis in the first patient treated with Bria-OTS, their personalized off-the-shelf immunotherapy for metastatic breast cancer. The 78-year-old patient with hormone receptor-positive, HER2-negative metastatic breast cancer showed 100% resolution of lung metastasis, maintained at 2, 4, and 6 months after treatment.
The patient, who had multiple prior treatment failures, has received 12 cycles of Bria-OTS monotherapy with no treatment-limiting toxicities. This milestone was achieved at the lowest dose level, demonstrating strong single-agent activity in a challenging patient population.
BriaCell Therapeutics (NASDAQ: BCTX) has reported impressive survival data from its Phase 2 clinical study of Bria-IMT in metastatic breast cancer patients. The study showed that 52% of the most recent 25-patient cohort survived beyond one year, surpassing current standard of care expectations. Notably, 11 patients remain alive, with two remarkable cases reaching 38.3 and 30.3 months of survival.
The study included heavily pre-treated patients who had previously failed multiple therapies, including checkpoint inhibitors and antibody-drug conjugates. The median number of prior treatments was 6, and importantly, no treatment discontinuations related to Bria-IMT have been reported, suggesting a well-tolerated profile.
BriaCell Therapeutics (NASDAQ: BCTX) has expanded its pivotal Phase 3 clinical trial for advanced metastatic breast cancer treatment by adding two major cancer centers: Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, contributing 30 additional satellite locations. The study now encompasses 58 active clinical sites across 15 states.
The trial evaluates BriaCell's lead candidate Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice. Patient enrollment is expected to complete by late 2025 or early 2026, with potential top-line data release in H1-2026. The study's primary endpoint will analyze overall survival after 144 patient events, with positive results potentially leading to full approval and marketing authorization.
BriaCell Therapeutics (NASDAQ: BCTX) has received a positive safety review recommendation from the independent Data Safety Monitoring Board (DSMB) for its pivotal Phase 3 study of Bria-IMT™ plus immune checkpoint inhibitor in metastatic breast cancer. This marks the third consecutive positive recommendation from the DSMB, which found no safety concerns and recommended the study continue without modifications.
The study is being conducted under FDA Fast Track Designation, highlighting the significant unmet medical need in metastatic breast cancer patients. The DSMB reviews occur quarterly as per study protocol, and this latest recommendation further validates the favorable safety profile of BriaCell's immunotherapy treatment.